Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 5,327 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
oblimersen sodium, imatinib mesylate, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Non Small Cell Lung Cancer, CNS Progression
Interventions
Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Post-operative Pain
Interventions
Dronabinol 2.5mg Cap, Placebo
Drug
Lead sponsor
Jeffrey L Gum MD
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Conditions
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions
Continuous Low-Dose IV Unfractionated Heparin Infusion
Drug
Lead sponsor
Robert F. James
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
Conditions
HIV-1-infection
Interventions
Albuvirtide, 3BNC117, Baseline ART
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more
Conditions
Arteriovenous Malformations (Extracranial)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Hepatic Encephalopathy
Interventions
sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Fresno, California • Loma Linda, California • Odessa, Texas
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Pirtobrutinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Flotetuzumab, Donor lymphocyte infusion
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
ASP8374, cemiplimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 1 more
Conditions
Metastatic Renal Cell Cancer
Interventions
Axitinib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Duarte, California • Cleveland, Ohio • Columbus, Ohio + 1 more
Conditions
Chronic Low-back Pain
Interventions
Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
Device · Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Colorectal Adenocarcinoma Metastatic to the Liver
Interventions
Floxuridine (FUDR), Irinotecan (CPT-11), FLUOROURACIL, PANITUMUMAB, DEXAMETHASONE, Leucovorin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Conditions
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy
Drug · Radiation
Lead sponsor
Aaron Wolfson
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Miami, Florida
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial

NCT03907410
Conditions
Medication Adherence, Asthma in Children
Interventions
Nominal Financial Incentives, Daily Adherence Reminders/Adherence Performance Feedback
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma
Interventions
Ketogenic Diet, Metformin
Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
New York, New York
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions
Larotrectinib monotherapy, 131I therapy
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 3 more